FDA gets 24-hour rule to catch contaminated baby formula before it reaches shelves

What it does

This bill requires infant formula manufacturers to notify the FDA within one business day if testing detects harmful microorganisms in finished formula, and to consult with the FDA on isolating and disposing of contaminated product. It also requires the FDA to respond within one business day and confirm within 90 days that manufacturers are investigating and fixing the problem. The bill adds reporting requirements so the FDA tracks infant formula supply and safety over five years.

Why we flagged it

The bill's core mechanism is mandatory rapid notification and FDA oversight of contaminated infant formula, with no carve-outs or exemptions. It is a straightforward consumer-protection and public-health measure.

What the text implies

• Manufacturers may face operational pressure to increase testing frequency and speed, potentially raising formula costs if compliance expenses are passed to consumers.
• The 1-business-day notification window is tight; manufacturers with inadequate lab capacity or geographic distance from testing facilities may struggle to comply.
• FDA resource demands increase significantly (1-business-day response, 90-day verification, quarterly reporting for 5 years); underfunded FDA may delay responses despite statutory timelines.
• The bill references a January 2025 FDA report on infant formula resiliency but does not mandate implementation of its recommendations—progress reports may reveal gaps without enforcement.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary families with infants gain faster detection and removal of contaminated formula from the market, reducing exposure to dangerous microorganisms. The bill imposes compliance costs on manufacturers but no direct cost to consumers, and the public health benefit—preventing infant illness or death from contaminated formula—is substantial.

Who stands to gain

• infant formula manufacturers (compliance cost offset by reduced recall liability and market confiden
• laboratory testing services (increased demand for rapid microorganism testing)

Named in the bill

FDA (Food and Drug Administration), Department of Agriculture, Senate Committee on Health, Education, Labor, and Pensions, Senate Committee on Agriculture, Nutrition, and Forestry, House Committee on Energy and Commerce, House Committee on Agriculture, infant formula manufacturers, Federal Food, Drug, and Cosmetic Act, 21 CFR 106.55(e)

Where it stands

9 cosponsors: 6 Democrats, 3 Republicans.

• Jan 28, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Jan 28, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
• Jan 15, 2026 — Reported out of committee · Congress.gov: “Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature…”
• Apr 28, 2026 — Passed the Senate · Congress.gov: “Passed Senate with an amendment and an amendment to the Title by Unanimous Consent.”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 3 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $684,000 in lobbying spend. A filing names 5 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Gary Peters, the sponsor, reported $-186,100 in PAC receipts in the 2026 cycle.

• Food Marketplace Inc — $584,000 on 1 filing
• Bobbie Baby, Inc. — $100,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.